Get the Stockscreener App
7.09
8.40%
-0.65
After Hours:
7.06
-0.03
-0.42%
Aura Biosciences Inc stock is traded at $7.09, with a volume of 677.88K.
It is down -8.40% in the last 24 hours and up +6.94% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$7.74
Open:
$7.74
24h Volume:
677.88K
Relative Volume:
1.16
Market Cap:
$733.36M
Revenue:
-
Net Income/Loss:
$-112.39M
P/E Ratio:
-4.0209
EPS:
-1.7633
Net Cash Flow:
$-91.64M
1W Performance:
+3.05%
1M Performance:
+6.94%
6M Performance:
+37.40%
1Y Performance:
+8.08%
1-Day Range:
$7.06
$7.87
1-Week Range:
$6.53
$7.87
52-Week Range:
$4.73
$9.535
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
7.09 | 734.40M | 0 | -112.39M | -91.64M | -1.7633 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Resumed | Evercore ISI | Outperform |
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
View All
Aura Biosciences Inc Stock (AURA) Latest News
Executive at Aura Biosciences (AURA) receives 14,858 RSUs - Stock Titan
Aura Biosciences, Inc. ($AURA) Former President, CEO and Director 2025 Pay Revealed - Quiver Quantitative
Form DEF 14A AURA BIOSCIENCES For: 29 June By Investing.com - Investing.com South Africa
Aura Biosciences (NASDAQ: AURA) sets vote on 500M share authorization and equity plan tweak - Stock Titan
Aura Biosciences Inc Actuals & Estimates (BOATS:AURA) - TradingView
Aura Biosciences Inc Actuals & Estimates (NASDAQ:AURA) - TradingView
AURA Forecast — Price Target — Prediction for 2027 - TradingView
Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones - Stock Traders Daily
Aura Biosciences Inc (AURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aura Biosciences Inc (AURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aura Biosciences Inc (AURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aura Biosciences Inc (AURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aura Biosciences Inc (AURA) Institutional Confidence - TradingKey
Aura Biosciences Inc (AURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AURA News | AURA BIOSCIENCES INC (NASDAQ:AURA) - ChartMill
Aura Biosciences Inc (AURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aura Biosciences (AURA) seeks charter increase to 500M shares; equity-plan tweak - Stock Titan
Aura Biosciences Inc (AURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aura Biosciences Inc (AURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Top Aura Biosciences Executive Quietly Unloads Shares in Notable Insider Move - TipRanks
Aura Biosciences (AURA) files Form 144 to resell 37,500 RSU shares - Stock Titan
Tax-related Aura Biosciences (AURA) insider sale covers RSU withholding - Stock Titan
Aura Biosciences (AURA) director awarded 15,000 RSUs and 30,000 options - Stock Titan
Aura Biosciences (NASDAQ: AURA) director receives RSUs and 30,000 stock options - Stock Titan
Aura Biosciences (AURA) director receives RSUs and stock options - Stock Titan
Aura Biosciences (AURA) awards director RSUs and $6.21 stock options - Stock Titan
Technical Reactions to AURA Trends in Macro Strategies - Stock Traders Daily
Aura Biosciences (AURA) Gains 3% as Shares Bounce from SupportNHNL Ratio - newsline.com
Aura Biosciences, Inc. 8-K Filing Details for June 11, 2026: Emerging Growth Status and Shareholder Vote Submission 1821 – Minichart - Minichart
InvestingPro’s Fair Value spotted Aura Biosciences’ 47% decline By Investing.com - Investing.com
Aura Biosciences Announces Results of 2026 Annual Meeting - TipRanks
Shareholders back Aura Biosciences (NASDAQ: AURA) directors and auditor - Stock Titan
Aura Biosciences Inc. Q1 2026 Earnings: Wider-than-Expected Loss Marks Early-Stage Pipeline Progress - newsline.com
Aura Biosciences gears up for Bel-Sar filing as pivotal eye cancer trial advances - MSN
Trading the Move, Not the Narrative: (AURA) Edition - Stock Traders Daily
Aura Biosciences highlights Bel-Sar eye cancer strategy, mid-year bladder data - MSN
Aura Biosciences completes phase 3 enrollment for eye cancer drug By Investing.com - Investing.com India
AURA Technical Analysis & Stock Price Forecast - Intellectia AI
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma - The Manila Times
Aura Biosciences completes enrollment in Phase 3 trial for early choroidal melanoma treatment - Pluang
Aura Biosciences completes phase 3 enrollment for eye cancer drug - Investing.com
Eye cancer trial hits 108 patients as Aura tests new frontline therapy - Stock Titan
AURA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelinePost-Announcement Reaction - The Legal Advocate
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances - TradingView
AURA: Bel-sar leads innovation in ocular oncology with robust data and a strong financial runway - TradingView
H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Ken Fisher's Aura Biosciences Inc(AURA) Holding History - GuruFocus
(AURA) Volatility Zones as Tactical Triggers - Stock Traders Daily
AURA Q1 2026 Earnings: EPS Misses Estimates, Stock Rises 2.4% on Pre-Clinical ProgressBalance Sheet Strength - Newser
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aura Biosciences Inc Stock (AURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gibney Anthony S | See Remarks |
Jun 16 '26 |
Sale |
6.42 |
12,824 |
82,330 |
265,354 |
| Matrix Capital Management Comp | 10% Owner |
May 07 '26 |
Sale |
5.64 |
6,922,870 |
39,044,987 |
0 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):